# US 10,869,855 B2 · Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,869,855 B2 - Document ID: US10869855B2 - Status: Granted - Kind: B2 - Application number: 16/814,403 - Filed: 2020-03-10 - Published: 2020-07-02 - Granted: 2020-12-22 - Earliest claimed: 2012-07-26 - Assignees: The William M. Yarbrough Foundation - Applicants: Michael E. Silver - Inventors: Michael E. Silver - Web page: https://patentgrep.com/patent/US10869855B2 ## CPC - A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K 31/16: Amides, e.g. hydroxamic acids - A61K 31/195: having an amino group - A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer. In a preferred embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: ## Claims ### Claim 1 A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, comprising the step of: administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer, to, in turn, eliminate, modulate, and/or reduce macrophage migration inhibitory factor cytokine and/or its biological activity. ### Claim 2 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. ### Claim 3 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the isothiocyanate functional surfactant comprises a lysine derivative, wherein the lysine derivative comprises an α-nitrogen and a ε-nitrogen, and wherein an alkyl and/or alkanoyl substituent comprising at least approximately 8 carbon atoms is associated with the α-nitrogen, and further wherein at least one isothiocyanate functional group is associated with the ε-nitrogen. ### Claim 4 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the isothiocyanate functional surfactant is represented by the following chemical structure: wherein the protonated form of the surfactant comprises a non-polar moiety (NP) and a polar moiety (P), and wherein at least one isothiocyanate functional group (NCS) is associated with the polar and/or non-polar moiety. ### Claim 5 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: wherein R1 comprises an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer; wherein R2 comprises NCS; and wherein R3-R5 are the same or different and comprise H; OH; an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer with the proviso that at least one of R3-R5 comprise an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 8 to approximately 25 carbon atom(s). ### Claim 6 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: wherein R1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R2 is selected from the group consisting of NCS; and wherein R3-R5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms. ### Claim 7 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: wherein X comprises an integer ranging from approximately 1 to approximately 25, and wherein Y comprises an integer ranging from approximately 6 to approximately 25. ### Claim 8 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: ### Claim 9 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the protonated form of the isothiocyanate functional surfactant is represented by at least one of the following chemical structures: ### Claim 10 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the isothiocyanate functional surfactant is represented by the following chemical structure: wherein R1 comprises an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer; wherein R2 comprises NCS; wherein R3-R5 are the same or different and comprise H; OH; an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer with the proviso that at least one of R3-R5 comprise an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 8 to approximately 25 carbon atom(s), wherein X comprises a counter cation such as, but not limited to, alkali metals, alkaline earth metals, transition metals, s-block metals, d-block metals, p-block metals, NZ4+, wherein Z comprises, H, R6, OR6, and wherein R6 comprises an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer. ### Claim 11 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the isothiocyanate functional surfactant is represented by the following chemical structure: wherein R1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R2 is selected from the group consisting of NCS; and wherein R3-R5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms; and wherein X comprises a counter cation. ### Claim 12 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the isothiocyanate functional surfactant is administered to the patient at least one of orally, intravenously, intramuscularly, intrathecally, cutaneously, subcutaneously, transdermally, sublingually, buccally, rectally, and nasally. ### Claim 13 (depends on 12) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 12, wherein the amount of isothiocyanate functional surfactant topically administered to the patient ranges from approximately 0.5 nmol/cm2 to approximately 10 μmol/cm2. ### Claim 14 (depends on 13) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 13, wherein the isothiocyanate functional surfactant is a topical preparation selected from the group consisting of ointment, cream, emulsion, lotion and gel. ### Claim 15 (depends on 14) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 14, wherein the isothiocyanate functional surfactant further comprises one or more pharmaceutical, biological or molecular biological active agents. ### Claim 16 (depends on 1) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 1, wherein the patient is a mammal. ### Claim 17 (depends on 16) The method for treating benign prostatic hyperplasia, prostatitis, and/or prostate cancer according to claim 16, wherein the mammal is a human.